Tuesday, 21 January 2020 14.00 - 15.30 h
For over the past 3 years, the testing of metallic impurities has been the subject of ICH's efforts on harmonisation. The committee is responsible for the creation of guidelines for the pharmaceutical and APIs industry to be used - when finalised - in the three economic zones Europe, USA and Japan. The publication of a final guideline goes through a 4-step process; in the fifth and last step, the document is incorporated (i.e. "adopted") into the respective guidelines fund by the three partners.
At the end of 2011, the draft of a ICH Q3D guideline was published as a pre-step 2 document which first contained the requirements on the testing of metallic impurities in medicinal products and APIs. At the end of July 2013, the Draft Consensus Guideline "Guideline for Elemental Impurities" (step 2b document) was released and open for comments 6 months long. After considering all the comments received, the corresponding adaptation of the content and its publication should take place in June 2014. That was at least the working plan presented by the ICH Expert Working Group in the agenda of the ICH meeting which took place from 31 May till 5 June in Minneapolis. It stated: "Step 4 of the ICH Q3D Guideline is expected in June 2014". If this deadline can't be respected, the adoption of the finalised guideline would be expected only in autumn this year.
The delay in the acceptation and publication of the ICH Q3D guideline (step 4) also has consequences on the revision of some important national regulations in the three ICH regions.
The current situation is unsatisfactory for the pharmaceutical industry as it is not clear how different the expected final ICH Q3D guideline is from last year's published draft (step 2). Furthermore, long-term preparation (investments in technology and resources) is difficult. In particular, uncertainties remain with regard to large volume parenterals and the inclusion of already marketed medicinal products. Another issue concerns the different standards used in ICH and non-ICH regions which will emerge when the final ICH Q3D will be binding. How should global pharmaceutical industry as well as supervisory and licensing authorities manage that? The answer to that question is currently still open.